Skip to main content

What the FDA labels say about taking them together

Atazanavir and cabazitaxel

Cabazitaxel's FDA label of October 7, 2025 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name cabazitaxel. The cabazitaxel label: “Strong CYP3A inhibitors may increase plasma concentrations of cabazitaxel.”

Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the cabazitaxel FDA label on DailyMed (effective October 7, 2025, Sanofi-Aventis U.S. LLC).

What does the atazanavir label say about cabazitaxel?

Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name cabazitaxel in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed

What does the cabazitaxel label say about atazanavir?

Cabazitaxel label, drug interactions

Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase plasma concentrations of cabazitaxel.

Source: FDA drug label (Jevtana), Sanofi-Aventis U.S. LLC, effective October 7, 2025 (SPL set de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

4Atazanavir generic labelers
0Cabazitaxel generic labelers
AtazanavirCabazitaxel
Labeled forHIVProstate cancer
Boxed warningNoYes
Pharmacy cost (NADAC)$2.23 per capsule 300 mg capsulen/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?